Antibody therapy for COVID-19.
Curr Opin Allergy Clin Immunol
; 21(6): 553-558, 2021 12 01.
Статья
в английский
| MEDLINE | ID: covidwho-2161180
ABSTRACT
PURPOSE OF REVIEW To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period. RECENT FINDINGS:
Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results.SUMMARY:
Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding domain of the spike protein currently appears to provide the best form of antibody therapy, Immunoglobulin A dimers and Immunoglobulin M pentamers also show promising preliminary therapeutic results.
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
SARS-CoV-2
/
COVID-19
/
Antibodies, Monoclonal
Тип исследования:
Прогностическое исследование
/
Рандомизированные контролируемые испытания
Пределы темы:
Люди
Язык:
английский
Журнал:
Curr Opin Allergy Clin Immunol
Тематика журнала:
Аллергология и иммунология
Год:
2021
Тип:
Статья
Документы, близкие по теме
MEDLINE
...
LILACS
LIS